Americord is a leader in the advancement of umbilical cord blood, cord tissue, and placental tissue banking. As a private bank, Americord collects, processes, and stores newborn stem cells for future medical or therapeutic use by the family that saves them. Americord is committed to pioneering the development of new cord blood banking technologies. Under the direction of its Executive Medical Director, Dr. Robert Dracker, the company developed Cord Blood 2.0, which uses the company’s proprietary Gravity Stand™ combined with a proprietary extraction process to harvest up to twice as many stem cells compared to a traditional cord blood collection.  Americord is registered with the FDA and operates in all 50 states. The company’s laboratory is CLIA Certified, accredited by the AABB and complies with all federal and state guidelines and applicable licenses.

In 2019, Americord officially launched its field sales function to drive future revenue growth through a distributed sales force around the country. In addition, the company launched its new Placenta 2.0 product to enable the banking of stem cells that can help any first-or-second-degree relative of a customer. Lastly, Americord significantly increased its revenue, securing its 5th straight year on the Inc. 5000 list of America’s fastest growing private companies with 3-year growth of 193% to $7.2 million.